Medical articles today

/* 728x15, */

Bone Soul Cell Therapy May Be Favoring For Patients With Ischemic Affection Disease

/* 468x60, */

The injection of bone centre cells into the feelings of patients with chronic myocardial ischemia (reduced blood flow to some areas of the heart) was associated with modest improvements in blood flow and utility of the left ventricle, according to a study in the May 20 issue of JAMA.
Bone marrow cell therapy is currently being investigated as a new therapeutic option for patients with ischemic passion disease. Two small-sized studies assessed the consequence of this therapy in patients with chronic myocardial ischemia, however with varying results, according to background confidence in the article.
Jan machine Ramshorst, M.D., of Leiden University Medical Center, the Netherlands, and colleagues assessed the corollary of intramyocardial (within the heart wall) bone marrow cell injection on myocardial perfusion (the flow of blood to the emotions muscle) and left ventricular (LV) function in patients with chronic ischemia who were not eligible for conventional treatment. The trial included 50 patients (average age, 64 years; 43 men), who were randomized to collect about 8 injections of either bone marrow cells or placebo solution.
At 3-month follow-up, when the two groups were compared, the improvement in summed stress score (a measure of myocardial perfusion) was significantly worthier in the bone marrow-cell treated patients as compared with placebo-treated patients. Magnetic resonance imaging indicated that the absolute increase in left ventricular ejection fraction (LVEF; a degree of how fresh the left ventricle of the love pumps with each contraction) was significantly larger in bone nucleus cell-treated patients. A quality-of-life score increased at 3 and 6 months in bone pith cell-treated patients, compared with a smaller accretion in the placebo group. There was also in a superior way improvement in exercise competence in the bone marrow cell group.
"In summary, the results of this randomized, double-blind, placebo-controlled trial evince that intramyocardial bone marrow cell injection in patients with chronic ischemia is associated with heavy improvements in anginal symptoms, myocardial perfusion, and LV function," the authors write.
JAMA 2009;301[19]:1997-2004.
/* 468x60, */


patients, patients chronic, patients ischemic, favoring patients, patients compared, patients average, included patients, patients score, therapy patients, option patients
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy